In a phase 1b/2 prospective clinical trial, 44% of participants with MDS or AML attained a CR, with patients harboring TP53 mutations preferentially attaining CR with eprenetapopt compared to patients with TP53 wild-type disease (69% vs. 25%); the median OS was 10.8 months [80]. The gene discussed is TP53; the disease is myelodysplastic syndrome.